EYEN Eyenovia Inc
2,841
$0.7499
$0.071
(8.65%)
| Watchers | 2,841 |
| 52-Wk Low | $0.501 |
| 52-Wk High | $3.31 |
| Market Cap | $40.4M |
| Volume | 1.02M |
| 52-Wk High | $3.31 |
| 52-Wk Low | $0.501 |
Eyenovia to feature commercial products, Optejet Dispenser at eyecare meetingsThe Fly • about 1 month ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
Company to demonstrate Mydcombi and Avenova and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting...
Eyenovia, Inc. (NASDAQ:EYEN - Get Free Report) major shareholder Stuart M. Grant bought 100,000 shares of the stock in a transaction on Thursday, March 28th. The stock was purchased at an average...
Eyenovia, Inc. (NASDAQ:EYEN Free Report) Investment analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Eyenovia in a research report issued to clients and...
Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript...
Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to...
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion...
Eyenovia, Inc. (NASDAQ:EYEN Get Free Report) major shareholder Stuart M. Grant acquired 10,717 shares of the stock in a transaction dated Friday, March 8th. The stock was acquired at an...
Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical...